TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or metastatic disease).~* Women who are not of childbearing potential.~* ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice).~* HER2-negative breast cancer based on local laboratory results (test as per local practice or local guidelines).~* Patients must be appropriate candidates for letrozole therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Adequate bone marrow function.~* Adequate liver function~* Adequate renal function.~Exclusion Criteria:~* Known hypersensitivity to letrozole, or any of its excipients, or to any palbociclib excipients.~* Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry.~* Prior treatment with any CDK inhibitor.~* Previous participation in a palbociclib clinical study.~* Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.~* QTc \>480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.~* High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment.~* Diagnosis of any second invasive malignancy within the last 3 years prior to enrollment. Note: patients with adequately treated basal cell or squamous cell skin cancer, a history of intraepithelial neoplasia or in situ disease (eg, carcinoma in situ of the cervix or melanoma in situ) may enter.~* Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, brain metastases are permitted.~* Other severe acute or chronic medical or psychiatric conditions.~* Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees directly involved in the conduct of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + Letrozole (Type: EXPERIMENTAL): palbociclib and letrozole combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histological or cytological diagnosis of AOC~* Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC ≥ 90 days of duration of response for first-line therapy~* Measurable disease defined by RECIST criteria~* ECOG Performance Status of 0, 1, or 2~* Life expectancy \> 3 months~* Adequate bone marrow, Renal, Hepatic reserve:~  * absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL~ * platelet count ≥ 100,000 cells/μL~ * hemoglobin ≥ 9 g/dL~ * Total bilirubin ≤ 1.5 X ULN~ * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 X ULN~ * Alkaline Phosphatase (ALP) ≤ 2.0 X ULN~ * Serum creatinine \< 1.5mg/dL or calculated creatinine clearance \> 60mL/min~* Signed a written informed consent~Exclusion Criteria:~* Active infection~* Symptomatic brain lesion~* Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases~* Prior anticancer therapy within 4 weeks before enroll~* Active pregnancy test and Pregnant or nursing women~* Participation in any investigational drug study within 28 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topotecan (Type: ACTIVE_COMPARATOR): Topotecan
- Camtobell (Type: ACTIVE_COMPARATOR): Belotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Glycemic Index of Ethiopian Honey

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of diabetes Disease~* Must be able to drink the honeys and reference glucose~Exclusion Criteria:~* Overweight, dieting, smoking, a family history of diabetes, pregnant, metabolic disorders, suffering from any illness or food allergy and regularly taking medication.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- Provision of experimental honeys (Type: EXPERIMENTAL): Eight experimental monofloral honeys and reference glucose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccination and Oral Anticoagulant Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* OA Treatment~* Stable anticoagulation (previous two controls in range)~* Presence of indication for Influenza Vaccination~* Life expectancy \> 6 months~* Signed Informed consent~Exclusion Criteria:~* Absence of stable anticoagulation~* Absence of indication for Influenza Vaccination~* Life expectancy \< 6 months~* Denied Informed Consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Obsessive Compulsive Disorder in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV Diagnosis of obsessive compulsive disorder~* CYBOCS total score greater than 16~Exclusion Criteria:~* Other primary or co-primary psychiatric disorder~* Pervasive developmental disorder or disorders, including Asperger's Syndrome~* Thought disorder~* Prior failed trial of cognitive-behavioral therapy~* Has pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) or maintenance antibiotic for obsessive-compulsive disorder~* Mental retardation~* Pregnancy

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- MedMgmt+CBT (Type: EXPERIMENTAL): Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
- MedMgmt+I-CBT (Type: EXPERIMENTAL): Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
- MedMgmt Only (Type: ACTIVE_COMPARATOR): Participants will receive the intervention SRI medication management with a psychiatrist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Pathologically confirmed NMIBC with CIS (with or without Ta/T1 disease)~* Unresponsive to prior BCG therapy (Lerner 2015) defined as persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the sub- epithelial connective tissue) disease within 12 months of completion of adequate BCG therapy. An assessment within 15 months can also qualify when no assessment was performed within 12 months after completion of adequate BCG therapy.~  * Adequate BCG is defined as at least 5 treatments with induction BCG followed by at least 2 BCG treatments as reinduction or maintenance~* Ineligible for radical cystectomy or refusal of radical cystectomy~* Adequate organ function~Key Exclusion Criteria:~* Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant~* Prior treatment with adenovirus-based cancer therapy~* Prior therapy with or intolerant to prior checkpoint inhibitor therapy~* Clinically significant or active cardiac disease~* Active autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 25, patients will receive weekly x 3 treatments every 3 months through Week 49 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 6 weeks for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study~* Chronic genotype 1 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Absence of cirrhosis~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Infection with hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol~* For HIV-1/HCV co-infected individuals:~  * Opportunistic infection within 6 months prior to screening~ * Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline~ * Treatment with an antiretroviral (ARV) regimen other than one of those listed in the study protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
- LDV/SOF Coinfected with HIV-1 (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
- LDV/SOF+RBV Retreatment (Type: EXPERIMENTAL): Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Physical Exercise in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual (DSM) - 5 diagnosis of schizophrenia or schizoaffective disorder;~* age 40-65;~* screened for physical health risks (i.e., no serious heart condition, dizziness, bone or joint problems posing safety concerns, ambulatory limitations);~* clinically stable (e.g., no inpatient hospitalizations for 3 months prior to enrollment; no change in type of antipsychotic medication in the past 4 weeks)~Exclusion Criteria:~* evidence of alcohol or substance use disorder (moderate or greater severity) per DSM-5 criteria in the past 3 months;~* clinically significant neurological disease as determined by medical history (e.g., seizure disorder);~* history of serious head injury with loss of consciousness \>1 hour;~* participation in an exercise program within past 6 months;~* not able to understand spoken and written English sufficiently to comprehend consent procedures.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Physical exercise (Type: EXPERIMENTAL): Participants participate in brisk walking exercises.
- Stretching exercise (Type: ACTIVE_COMPARATOR): Participants participate in non-aerobic, non-Yoga stretching exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For MAIN period (NN1250-3582):~* Type 2 diabetes mellitus for at least 6 months~* Ongoing daily treatment with insulin (premix, self-mix, basal only, basal bolus) for at least 3 months with/without oral anti-diabetics drug (OAD) prior to trial start~* HbA1c 7.0-10.0 % (both inclusive)~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~* For EXTENSION period (NN1250-3667):~* Completion of the 52 week treatment period in NN1250-3582~Exclusion Criteria:~* For MAIN period (NN1250-3582):~* Treatment with other insulin regimens than premix, self-mix, basal only, basal bolus within 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bongros-BMP Compared to Bio-oss for Regeneration of Alveolar Bone Tissue After Maxillary Sinus Floor Augmentation

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
None

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Novosis(bongros/BMP-2) (Type: EXPERIMENTAL): None
- Bio-oss (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20-40 years old~* PCOS infertile women resistant to CC for3 cycles~Exclusion Criteria:~* presence of medical disorders as diabetes, hypertension, cardiac problems, liver or kidney diseases, hyperprolactinemia or thyroid dysfunction.~* use of gonadotropins before~* previous ovarian drilling~* presence of urinary symptoms especially bloody urine

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- arm 1:letrozole-pioglitazone -metformin group (Type: ACTIVE_COMPARATOR): Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
- arm 2: clomiphene citrate-pioglitazone-metformin (Type: ACTIVE_COMPARATOR): Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or TEE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (defined as anything less than the criterion for Grade A). The subject was counted as healed if endoscopy findings did not meet the Grade A criterion.~Exclusion Criteria:~* Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study~* Use of antacids (except for study supplied) throughout the study.~* Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.~* Need for continuous anticoagulant therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meta-analysis of Stannous Fluoride and the Effects on Gingival Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Subjects were excluded from this study for the following reasons;~* pregnancy,~* rampant caries,~* severe periodontitis,~* at discretionary of the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stannous Fluoride Dentifrice (Type: None): Twice daily brushing
- Positive Control Dentifrice (Type: None): Twice daily brushing
- Negative Control Dentifrice (Type: None): Twice daily brushing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Gene Therapy Study for Hemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent and comply with requirements of the study~* Males ≥18 y.o. with confirmed diagnosis of hemophilia B (≤2 IU/dL or ≤2% endogenous factor IX)~* Received ≥50 exposure days to factor IX products~* A minimum average of 4 bleeding events per year requiring episodic treatment of factor IX infusions or prophylactic factor IX infusions~* No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein~* Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences~Exclusion Criteria:~* Evidence of active hepatitis B or C~* Currently on antiviral therapy for hepatitis B or C~* Have significant underlying liver disease~* Have serological evidence\* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (\* subjects who are HIV+ and stable with CD4 count \>200/mm3 and undetectable viral load are eligible to enroll)~* Neutralizing antibodies reactive with AAV-Spark100 above and/or below a defined titre~* Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational drug within the last 12 weeks~* Unable or unwilling to comply with study assessments

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPK-9001 (Type: EXPERIMENTAL): Single intravenous (i.v.) infusion of SPK-9001 \[an adeno-associated viral (AAV) vector with human factor IX gene\] Intervention: Gene Therapy / Gene Transfer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete